Could a new drug tame dangerous brain blood vessel clusters?
NCT ID NCT05085561
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests an experimental drug called REC-994 in adults with symptomatic cerebral cavernous malformation (CCM), a condition where clusters of abnormal blood vessels in the brain can cause bleeding, seizures, and other symptoms. Participants receive either a low or high dose of REC-994 or a placebo for up to a year, with a long-term extension phase. The study measures safety, symptom changes, and bleeding events to see if the drug can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REC-994
What this could lead to
If successful, REC-994 could become the first drug treatment to reduce symptoms and bleeding events in people with cerebral cavernous malformation.
What could go wrong
This is a small, early-phase trial. The drug may not prove more effective than placebo, and long-term safety is still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL CAVERNOUS MALFORMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Florida
Port Saint Lucie, Florida, 34987, United States
-
Columbia University Medical Center
New York, New York, 10027, United States
-
Emory
Atlanta, Georgia, 30322, United States
-
Lyerly Neurosurgery
Jacksonville, Florida, 32207-8202, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
The University of Texas Southwestern Medical Center
Dallas, Texas, 75390-8855, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19104, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Florida
Gainesville, Florida, 32608, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15260, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Valley Hospital
Ridgewood, New Jersey, 07450, United States
-
Xenoscience Inc
Phoenix, Arizona, 85004, United States